Harakiri, BCL2 Interacting Protein (Contains Only BH3 Domain) (HRK) Peptide

Details for Product No. ABIN499949
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Protein Name
Synonyms DP5, HARAKIRI, Bid3, AI838259, harakiri, Dp5
Origin
Human
(1)
Application
Control Peptide (CP)
Pubmed 3 references available
Catalog no. ABIN499949
Quantity 50 µg
Price
170.50 $   Plus shipping costs $45.00
Shipping to United States (Change)
Availability Will be delivered in 6 to 8 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Specificity 15 amino acids near the center of human Hrk.
Alternative Name Harakiri / HRK
Background Alternate names: Activator of apoptosis harakiri, BH3-interacting domain-containing protein 3, BID3, Neuronal death protein DP5
Gene ID 8739
NCBI Accession NP_003797.1
UniProt O00198
Application Notes Hrk peptide is used for blocking the activity of Hrk antibody. It usually blocks the antibodyactivity completely in Western blot by incubating the peptide with equal volume ofantibody for 30 min at 37°C. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Format Liquid
Concentration 0.2 mg/mL
Buffer PBS pH7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Preservative Sodium azide
Handling Advice Avoid repeated freezing and thawing.
Storage -20 °C
Storage Comment Store at -20°C.
Expiry Date 12 months
Background publications Pflanz, Timans, Cheung et al.: "IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells." in: Immunity, Vol. 16, Issue 6, pp. 779-90, 2002 (PubMed).

Pflanz, Hibbert, Mattson et al.: "WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 4, pp. 2225-31, 2004 (PubMed).

Hisada, Kamiya, Fujita et al.: "Potent antitumor activity of interleukin-27." in: Cancer research, Vol. 64, Issue 3, pp. 1152-6, 2004 (PubMed).

Reactivities (1)
back to top